Last reviewed · How we verify
Ramipril, Amlodipine and Atorvastatin
Ramipril, Amlodipine and Atorvastatin is a Small molecule drug developed by Midas Pharma GmbH. It is currently in Phase 1 development.
At a glance
| Generic name | Ramipril, Amlodipine and Atorvastatin |
|---|---|
| Sponsor | Midas Pharma GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramipril, Amlodipine and Atorvastatin CI brief — competitive landscape report
- Ramipril, Amlodipine and Atorvastatin updates RSS · CI watch RSS
- Midas Pharma GmbH portfolio CI
Frequently asked questions about Ramipril, Amlodipine and Atorvastatin
What is Ramipril, Amlodipine and Atorvastatin?
Ramipril, Amlodipine and Atorvastatin is a Small molecule drug developed by Midas Pharma GmbH.
Who makes Ramipril, Amlodipine and Atorvastatin?
Ramipril, Amlodipine and Atorvastatin is developed by Midas Pharma GmbH (see full Midas Pharma GmbH pipeline at /company/midas-pharma-gmbh).
What development phase is Ramipril, Amlodipine and Atorvastatin in?
Ramipril, Amlodipine and Atorvastatin is in Phase 1.